We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
With the completion of the Senate HELP Committee’s third and final markup on biomedical innovation legislation, a complete cures package is expected to hit the full Senate shortly. Read More
Apricus Biosciences has cut 30 percent of its workforce — including part of its executive team — following an unsuccessful Phase 2b trial evaluating fispemifene in men with secondary hypogonadism and sexual dysfunction. Read More
A final batch of biomedical innovation bills sailed through markup during a meeting of the Senate HELP Committee Wednesday, as lawmakers work toward passing a companion to the House’s 21st Century Cures Act this session. Read More